Search

Your search keyword '"Immovilli, P."' showing total 227 results
Start Over Author "Immovilli, P."
227 results on '"Immovilli, P."'

52. Erratum to: Incidence of neuroepithelial primary brain tumors among adult population of Emilia-Romagna Region, Italy

Author

Baldin, Elisa, Testoni, Stefania, de Pasqua, Silvia, Ferro, Salvatore, Albani, Fiorenzo, Baruzzi, Agostino, D’Alessandro, Roberto, Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Cerasoli, S., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Visani, M., Dall’Agata, M., Faedi, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Dazzi, C., Guidi, A. R., Zumaglini, F., Amadori, A., Pasini, G., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Fallica, E., Granieri, E., Latini, F., Lelli, G., Monetti, C., Saletti, A., Schivalocchi, R., Seraceni, S., Tola, M. R., Urbini, B., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, E. M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., Nobile, C., and On behalf of PERNO study group

Published
2017
Full Text
View/download PDF

53. Dimethyl fumarate‐induced lymphocyte count drop is related to clinical effectiveness in relapsing–remitting multiple sclerosis

Author

Tsantes, E., primary, Curti, E., additional, Ferraro, D., additional, Lugaresi, A., additional, Baldi, E., additional, Montepietra, S., additional, Immovilli, P., additional, Simone, A. M., additional, Mancinelli, L., additional, Strumia, S., additional, Vitetta, F., additional, Foschi, M., additional, Ferri, C., additional, Ferrarini, C., additional, Sola, P., additional, and Granella, F., additional

Published
2020
Full Text
View/download PDF

54. Breakthrough COVID-19 in people with multiple sclerosis on disease modifying treatments: Is it still a severe disease?

Author

Immovilli, Paolo, Schiavetti, Irene, Franceschini, Alessandro, De Mitri, Paola, Gelati, Lorenza, Rota, Eugenia, and Guidetti, Donata

Abstract

• B-cell suppressor treatments are associated with the risk of breakthrough COVID-19 in our cohort. • We did not observe any case of severe COVID-19: vaccination fully protected our cohort of people with multiple sclerosis against severe breakthrough disease. • B-cell suppressor treatments and EDSS were factors associated with low antibody titers after vaccination. Disease modifying treatments (DMTs) for multiple sclerosis (MS) are effective in preventing both relapses and disability progression. Highly effective treatments (HETs) are more effective than platform therapy in preventing confirmed disability progression (CDP), when used early. Infections may complicate HETs administration, and their prevention through vaccination is crucial in order to assure the safety of people with MS (pwMS). The aim of the present study is to describe the effect of MS DMTs on COVID-19 vaccination and the risk of breakthrough infection in a cohort of pwMS. This is a monocentric retrospective observational study conducted at the MS center of the Guglielmo da Saliceto Hospital in Piacenza, Italy. One hundred and fifty-seven (157) pwMS who received two doses of the SARS-CoV-2 vaccine (with 80.3 % receiving a booster dose) were included in the study. fifty-six pwMS (35.7 %) were females, the mean age was 48.6 (SD: 12.87) years, and 59 (37.6 %) had at least one comorbidity. Twenty-five (15.9 %) breakthrough infections were observed, with 17 (68.0 %) classified as mild and 8 (32.0 %) as moderate. A multivariable linear regression model confirmed that B-cell suppressor DMTs and EDSS were factors associated with the latest antibody titre. Patients treated with B-cell suppressors exhibited a risk almost four times higher for breakthrough infections compared to other patients, with a hazard ratio (HR) of 3.72 (95 % CI: 1.50 – 9.27) (p = 0.005). B-cell suppressor DMTs are associated with the risk of breakthrough COVID-19 in our cohort, but vaccination fully protected pwMS against severe breakthrough disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

59. Correction to: Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study (Journal of Neuro-Oncology, (2016), 128, 1, (157-162), 10.1007/s11060-016-2093-1)

Author

Franceschi, Enrico, Depenni, Roberta, Paccapelo, Alexandro, Ermani, Mario, Faedi, Marina, Sturiale, Carmelo, Michiara, Maria, Servadei, Franco, Pavesi, Giacomo, Urbini, Benedetta, Pisanello, Anna, Crisi, Girolamo, Cavallo, Michele A., Dazzi, Claudio, Biasini, Claudia, Bertolini, Federica, Mucciarini, Claudia, Pasini, Giuseppe, Baruzzi, Agostino, Brandes, Alba A., Baruzzi, A., Albani, F., Calbucci, F., D’Alessandro, R., Michelucci, R., Brandes, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Franceschi, E., Tosoni, A., Cavallo, Marino, Fiorica, F., Valentini, A., Depenni, R., Mucciarini, C., Crisi, G., Sasso, Enrico, Biasini, C., Cavanna, L., Guidetti, D., Marcello, Norina, Pisanello, A., Cremonini, A. M., Guiducci, G., de Pasqua, S., Testoni, S., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, Stefano, Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, Vincenzo, Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Faedi, M., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, Giuseppe, Cenni, P., Dazzi, C., Guidi, A. R., Zumaglini, F., Amadori, A., Pasini, G., Pasquinelli, Mario, Pasquini, Elena, Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, Greta, Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, Corrado, Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Colella, Margherita, Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M. R., Urbini, B., Zini, G., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, E. M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., and Nobile, C.

Subjects
Cancer Research, Oncology, Neurology, Neurology (clinical)
Published
2018

61. Dimethyl fumarate‐induced lymphocyte count drop is related to clinical effectiveness in relapsing–remitting multiple sclerosis.

Author

Tsantes, E., Curti, E., Ferraro, D., Lugaresi, A., Baldi, E., Montepietra, S., Immovilli, P., Simone, A. M., Mancinelli, L., Strumia, S., Vitetta, F., Foschi, M., Ferri, C., Ferrarini, C., Sola, P., and Granella, F.

Subjects
LYMPHOCYTE count, MAGNETIC resonance imaging, MULTIPLE sclerosis, DISEASE relapse, DIMETHYL fumarate
Abstract

Background and purpose: Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately 30% in relapsing–remitting multiple sclerosis (RRMS) patients. The relationship between this reduction and DMF effectiveness is controversial. The objective was to investigate if the decrease in absolute lymphocyte count (ALC) from baseline during DMF treatment is associated with clinical and magnetic resonance imaging (MRI) disease activity. A secondary aim was to evaluate ALC variations over time in a real‐life cohort of DMF‐treated patients. Methods: Demographic, laboratory, clinical and MRI data were collected in this observational multicentre study, conducted on RRMS patients treated with DMF for at least 6 months. Multivariate Cox models were performed to evaluate the impact of 6‐month ALC drop on time to no evidence of disease activity (NEDA‐3) status loss. NEDA‐3 is defined as absence of clinical relapses, MRI disease activity and confirmed disability progression. Results: In all, 476 patients (312 females, age at DMF start 38.4 ± 9.97 years) were analysed up to 5‐year follow‐up. A greater lymphocyte decrease was associated with a lower risk of NEDA‐3 status loss (hazard ratio 0.87, P = 0.01). A worse outcome in patients with lower ALC drop (<11.5%), compared with higher tertiles (11.5%–40.5% and >40.5%), was observed (P = 0.008). The nadir of ALC drop (−33.6%) and 35% of grade III lymphopaenia cases occurred after 12 months of treatment. Conclusion: A higher lymphocyte count drop at 6 months is related to better outcomes in DMF‐treated patients. A careful ALC monitoring should be pursued up to 24 months of treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

63. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study

Author

Franceschi, Enrico, Depenni, R., Paccapelo, Alexandro, Ermani, Mario, Faedi, M., Sturiale, Carmelo, Michiara, Maria, Servadei, F., Pavesi, Giacomo, Urbini, B., Pisanello, A., Crisi, G., Cavallo, Michele A., Dazzi, C., Biasini, C., Bertolini, F., Mucciarini, C., Pasini, G., Baruzzi, Agostino, Brandes, Alba A, Albani, F., Calbucci, F., D’Alessandro, R., Michelucci, R., de Pasqua, S., Testoni, S., Brandes, A., Franceschi, E., Tosoni, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Fiorica, F., Sasso, E., Cavanna, L., Guidetti, D., Marcello, N., Cremonini, A. M., Guiducci, G., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Guidi, A. R., Zumaglini, F., Amadori, A., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, Stefano, Nichelli, Paolo Frigio, Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Colella, M., Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M. R., Zini, G., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Silini, E. M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., Nobile, C., Franceschi, E., Depenni, R., Paccapelo, Alexandro, Ermani, Mario, Faedi, M., Sturiale, Carmelo, Michiara, Maria, Servadei, F., Pavesi, Giacomo, Urbini, B., Pisanello, A., Crisi, G., Cavallo, Michele A., Dazzi, C., Biasini, C., Bertolini, F., Mucciarini, C., Pasini, G., Baruzzi, Agostino, Brandes, Alba A., Albani, F., Calbucci, F., D’Alessandro, R., Michelucci, R., de Pasqua, S., Testoni, S., Brandes, A., Tosoni, A., Eusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Fiorica, F., Sasso, E., Cavanna, L., Guidetti, D., Marcello, N., Cremonini, A.M., Guiducci, G., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Guidi, A.R., Zumaglini, F., Amadori, A., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Colella, M., Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M.R., Zini, G., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Silini, E.M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., and Nobile, C.

Subjects
Oncology, medicine.medical_specialty, Cancer Research, medicine.medical_treatment, Dacarbazine, Population, Context (language use), NO, 03 medical and health sciences, 0302 clinical medicine, Elderly, Internal medicine, medicine, Temozolomide, Humans, MGMT methylation, Prospective Studies, Prospective cohort study, education, Promoter Regions, Genetic, Antineoplastic Agents, Alkylating, DNA Modification Methylases, Survival analysis, Aged, Aged, 80 and over, education.field_of_study, Radiotherapy, business.industry, Brain Neoplasms, Tumor Suppressor Proteins, Glioblastoma, Neurology (clinical), Neurology, DNA Methylation, Survival Analysis, Surgery, Radiation therapy, DNA Repair Enzymes, 030220 oncology & carcinogenesis, Concomitant, business, 030217 neurology & neurosurgery, medicine.drug
Abstract

The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear. We evaluated the outcome of patients >70 years in the context of the Project of Emilia-Romagna Region in Neuro-Oncology (PERNO), the first Italian prospective observational population-based study in neuro-oncology. For this analysis the criteria for selecting patients enrolled in the PERNO study were: age >70 years; PS 0–3; histologically confirmed GBM; postoperative radiotherapy (RT) after surgery with or without concomitant temozolomide (TMZ) or postsurgical TMZ alone. Between January 2009 and December 2010, 76 GBM elderly patients were identified in the prospective PERNO study. Twenty-three patients did not receive any treatment after surgery, and 53 patients received postsurgical treatments (25 patients received RT alone and 28 patients RT/TMZ). Median survival was 11.1 months (95 % CI 8.8–13.5), adding temozolomide concomitant and adjuvant to radiotherapy it was 11.6 months (95 % CI 8.6–14.6), and 9.3 months (95 % CI 8.1–10.6) in patients treated with RT alone (P = 0.164). However, patients with MGMT methylated treated with RT/TMZ obtained a better survival (17.2 months, 95 % CI 11.5–22.9) (P = 0.042). No difference in terms of survival were observed if patients with MGMT unmethylated tumor received RT alone, or RT/TMZ or, in MGMT methylated tumor, if patients received radiotherapy alone. In elderly patients RT/TMZ represent a widely used approach but it is effective with methylated MGMT tumors only.

Published
2016

64. Erratum to: Incidence of neuroepithelial primary brain tumors among adult population of Emilia-Romagna Region, Italy

Author

Baldin, E, Testoni, S, de Pasqua, S, Ferro, S, Albani, F, Baruzzi, A, D'Alessandro, R, PERNO study group Participants: Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Cerasoli, S., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., (Bologna), Visani M., Dall’Agata, M., Faedi, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A. ., (ForlI´-Cesena), Strumia S., Casmiro, M., Gamboni, A., (Faenza, Rasi F., RA), (Lugo, Cruciani G., Cenni, P., Dazzi, C., Guidi, A. R., (Ravenna), Zumaglini F., Amadori, A., Pasini, G., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., (Rimini), Viti B., (Cattolica, Sintini M., RN), Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., (Modena), Zunarelli E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., (Carpi, Stucchi C., MO), Iaccarino, C, Ragazzi, M., Rizzi, R., (Reggio Emilia), Zuccoli G., Api, P., Cartei, F., Fallica, E., Granieri, E., Latini, F., Lelli, G., Monetti, C., Saletti, A., Schivalocchi, R., Seraceni, S., Tola, M. R., (Ferrara), Urbini B., Giorgi, C., (Fidenza, Montanari E., PR), Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, Em., (Parma), Torelli P., Immovilli, P., Morelli, N., (Piacenza), Vanzo C., Nobile, C. (Padova)., Elisa Baldin, Stefania Testoni, Silvia de Pasqua, Salvatore Ferro, Fiorenzo Albani, Agostino Baruzzi, Roberto D’Alessandro, On behalf of PERNO study group, ELENA BONORA, and DARIO DE BIASE

Subjects
Psychiatry and Mental Health, Dermatology, General Medicine, Neurology (clinical)
Abstract

Unfortunately, some of the participants of the PERNO Study Group are missing in the original publication of the article. The correct details are given below: Participants: Agati R., Ambrosetto G., Bacci A., Baldin E., Baldrati A., Barbieri E., Bartolini S., Bellavista E., Bisulli F., Bonora E., Bunkheila F., Carelli V., Cerasoli S., Crisci M., Dall’Occa P., de Biase D., Ferro S., Franceschi C., Frezza G., GrassoV., Leonardi M., Marucci G., Morandi L., Mostacci B., Palandri G., Pasini E., Pastore Trossello M., Pession A., Poggi R., Riguzzi P., Rinaldi R., Rizzi S., Romeo G., Spagnolli F., Tinuper P., Trocino C., Visani M. (Bologna), Dall’Agata M., Faedi M., Frattarelli M., Gentili G., Giovannini A., Iorio P., Pasquini U., Galletti G., Guidi C., Neri W., Patuelli A.., Strumia S. (ForlÍ-Cesena), Casmiro M., Gamboni A., Rasi F. (Faenza, RA), Cruciani G. (Lugo, RA), Cenni P., Dazzi C., Guidi A.R., Zumaglini F. (Ravenna), Amadori A., Pasini G., Pasquinelli M., Pasquini E., Polselli A., Ravasio A., Viti B. (Rimini), Sintini M. (Cattolica, RN), Ariatti A., Bertolini F., Bigliardi G., Carpeggiani P., Cavalleri F., Meletti S., Nichelli P., Pettorelli E., Pinna G., Zunarelli E. (Modena), Artioli F., Bernardini I., Costa M., Greco G., Guerzoni R., Stucchi C. (Carpi, MO), Iaccarino C., Ragazzi M., Rizzi R., Zuccoli G. (Reggio Emilia), Api P., Cartei F., Fallica E., Granieri E., Latini F., Lelli G., Monetti C., Saletti A., Schivalocchi R., Seraceni S., Tola M.R., Urbini B. (Ferrara), Giorgi C., Montanari E. (Fidenza, PR), Cerasti D., Crafa P., Dascola I., Florindo I., Giombelli E., Mazza S., Ramponi V., Servadei F., Silini EM., Torelli P. (Parma), Immovilli P., Morelli N., Vanzo C. (Piacenza), Nobile C. (Padova).

Published
2017

65. Erratum to: Survival prediction in high-grade gliomas using CT perfusion imaging [J Neurooncol (2015) 123, 93-102, DOI 10.1007/s11060-015-1766-5]

Author

Yeung T. P. C., Wang Y., He W., Urbini B., Gafa R., Ulazzi L., Yartsev S., Bauman G., Lee T. -Y., Fainardi E., Baruzzi A., Albani F., Calbucci F., D'alessandro R., Michelucci R., Brandes A., Eusebi V., Ceruti S., Tamarozzi R., Emiliani E., Cavallo M., Franceschi E., Tosoni A., Fiorica F., Valentini A., Depenni R., Mucciarini C., Crisi G., Sasso E., Biasini C., Cavanna L., Guidetti D., Marcello N., Pisanello A., Cremonini A. M., Guiducci G., de Pasqua S., Testoni S., Agati R., Ambrosetto G., Bacci A., Baldin E., Baldrati A., Barbieri E., Bartolini S., Bellavista E., Bisulli F., Bonora E., Bunkheila F., Carelli V., Crisci M., Dall'occa P., de Biase D., Ferro S., Franceschi C., Frezza G., Grasso V., Leonardi M., Marucci G., Morandi L., Mostacci B., Palandri G., Pasini E., Pastore Trossello M., Pession A., Poggi R., Riguzzi P., Rinaldi R., Rizzi S., Romeo G., Spagnolli F., Tinuper P., Trocino C., Dall'agata M., Frattarelli M., Gentili G., Giovannini A., Iorio P., Pasquini U., Galletti G., Guidi C., Neri W., Patuelli A., Strumia S., Faedi M., Casmiro M., Gamboni A., Rasi F., Cruciani G., Cenni P., Dazzi C., Guidi A. R., Zumaglini F., Amadori A., Pasini G., Pasquinelli M., Pasquini E., Polselli A., Ravasio A., Viti B., Sintini M., Ariatti A., Bertolini F., Bigliardi G., Carpeggiani P., Cavalleri F., Meletti S., Nichelli P., Pettorelli E., Pinna G., Zunarelli E., Artioli F., Bernardini I., Costa M., Greco G., Guerzoni R., Stucchi C., Iaccarino C., Ragazzi M., Rizzi R., Zuccoli G., Api P., Cartei F., Colella M., Fallica E., Farneti M., Frassoldati A., Granieri E., Latini F., Monetti C., Saletti A., Schivalocchi R., Sarubbo S., Seraceni S., Tola M. R., Zini G., Giorgi C., Montanari E., Cerasti D., Crafa P., Dascola I., Florindo I., Giombelli E., Mazza S., Ramponi V., Servadei F., Silini E. M., Torelli P., Immovilli P., Morelli N., Vanzo C., Nobile C., Yeung T.P.C., Wang Y., He W., Urbini B., Gafa R., Ulazzi L., Yartsev S., Bauman G., Lee T.-Y., Fainardi E., Baruzzi A., Albani F., Calbucci F., D'alessandro R., Michelucci R., Brandes A., Eusebi V., Ceruti S., Tamarozzi R., Emiliani E., Cavallo M., Franceschi E., Tosoni A., Fiorica F., Valentini A., Depenni R., Mucciarini C., Crisi G., Sasso E., Biasini C., Cavanna L., Guidetti D., Marcello N., Pisanello A., Cremonini A.M., Guiducci G., de Pasqua S., Testoni S., Agati R., Ambrosetto G., Bacci A., Baldin E., Baldrati A., Barbieri E., Bartolini S., Bellavista E., Bisulli F., Bonora E., Bunkheila F., Carelli V., Crisci M., Dall'occa P., de Biase D., Ferro S., Franceschi C., Frezza G., Grasso V., Leonardi M., Marucci G., Morandi L., Mostacci B., Palandri G., Pasini E., Pastore Trossello M., Pession A., Poggi R., Riguzzi P., Rinaldi R., Rizzi S., Romeo G., Spagnolli F., Tinuper P., Trocino C., Dall'agata M., Frattarelli M., Gentili G., Giovannini A., Iorio P., Pasquini U., Galletti G., Guidi C., Neri W., Patuelli A., Strumia S., Faedi M., Casmiro M., Gamboni A., Rasi F., Cruciani G., Cenni P., Dazzi C., Guidi A.R., Zumaglini F., Amadori A., Pasini G., Pasquinelli M., Pasquini E., Polselli A., Ravasio A., Viti B., Sintini M., Ariatti A., Bertolini F., Bigliardi G., Carpeggiani P., Cavalleri F., Meletti S., Nichelli P., Pettorelli E., Pinna G., Zunarelli E., Artioli F., Bernardini I., Costa M., Greco G., Guerzoni R., Stucchi C., Iaccarino C., Ragazzi M., Rizzi R., Zuccoli G., Api P., Cartei F., Colella M., Fallica E., Farneti M., Frassoldati A., Granieri E., Latini F., Monetti C., Saletti A., Schivalocchi R., Sarubbo S., Seraceni S., Tola M.R., Zini G., Giorgi C., Montanari E., Cerasti D., Crafa P., Dascola I., Florindo I., Giombelli E., Mazza S., Ramponi V., Servadei F., Silini E.M., Torelli P., Immovilli P., Morelli N., Vanzo C., and Nobile C.

Subjects
PERNO, Gender, Glioblastoma, MGMT, Methylation
Abstract

Background: Clinical and molecular factors are essential to define the prognosis in patients with glioblastoma (GBM). O6-methylguanine-DNA methyltransferase (MGMT) methylation status, age, Karnofsky Performance Status (KPS), and extent of surgical resection are the most relevant prognostic factors. Our investigation of the role of gender in predicting prognosis shows a slight survival advantage for female patients. Methods: We performed a prospective evaluation of the Project of Emilia Romagna on Neuro-Oncology (PERNO) registry to identify prognostic factors in patients with GBM who received standard treatment. Results: A total of 169 patients (99 males [58.6%] and 70 females [41.4%]) were evaluated prospectively. MGMT methylation was evaluable in 140 patients. Among the male patients, 36 were MGMT methylated (25.7%) and 47 were unmethylated (33.6%); among the female patients, 32 were methylated (22.9%) and 25 were unmethylated (17.9%). Survival was longer in the methylated females compared with the methylated males (P = 0.028) but was not significantly different between the unmethylated females and the unmethylated males (P = 0.395). In multivariate analysis, gender and MGMT methylation status considered together (methylated females vs. methylated males; hazard ratio [HR], 0.459; 95% confidence interval [CI], 0.242-0.827; P = 0.017), age (HR, 1.025; 95% CI, 1.002-1.049; P = 0.032), and KPS (HR, 0.965; 95% CI, 0.948-0.982; P < 0.001) were significantly correlated with survival. Conclusions: Survival was consistently longer among MGMT methylated females compared with males. Gender can be considered as a further prognostic factor.

Published
2015

66. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power

Author

Franceschi, Enrico, primary, Tosoni, Alicia, additional, Minichillo, Santino, additional, Depenni, Roberta, additional, Paccapelo, Alexandro, additional, Bartolini, Stefania, additional, Michiara, Maria, additional, Pavesi, Giacomo, additional, Urbini, Benedetta, additional, Crisi, Girolamo, additional, Cavallo, Michele A., additional, Tosatto, Luigino, additional, Dazzi, Claudio, additional, Biasini, Claudia, additional, Pasini, Giuseppe, additional, Balestrini, Damiano, additional, Zanelli, Francesca, additional, Ramponi, Vania, additional, Fioravanti, Antonio, additional, Giombelli, Ermanno, additional, De Biase, Dario, additional, Baruzzi, Agostino, additional, Brandes, Alba A., additional, Baruzzi, A., additional, Albani, F., additional, Calbucci, F., additional, D'Alessandro, R., additional, Michelucci, R., additional, Brandes, A., additional, Eusebi, V., additional, Ceruti, S., additional, Fainardi, E., additional, Tamarozzi, R., additional, Emiliani, E., additional, Cavallo, M., additional, Franceschi, E., additional, Tosoni, A., additional, Fiorica, F., additional, Valentini, A., additional, Depenni, R., additional, Mucciarini, C., additional, Crisi, G., additional, Sasso, E., additional, Biasini, C., additional, Cavanna, L., additional, Guidetti, D., additional, Marcello, N., additional, Pisanello, A., additional, Cremonini, A.M., additional, Guiducci, G., additional, de Pasqua, S., additional, Testoni, S., additional, Agati, R., additional, Ambrosetto, G., additional, Bacci, A., additional, Baldin, E., additional, Baldrati, A., additional, Barbieri, E., additional, Bartolini, S., additional, Bellavista, E., additional, Bisulli, F., additional, Bonora, E., additional, Bunkheila, F., additional, Carelli, V., additional, Crisci, M., additional, Dall'Occa, P., additional, de Biase, D., additional, Ferro, S., additional, Franceschi, C., additional, Frezza, G., additional, Grasso, V., additional, Leonardi, M., additional, Marucci, G., additional, Morandi, L., additional, Mostacci, B., additional, Palandri, G., additional, Pasini, E., additional, Pastore Trossello, M., additional, Pession, A., additional, Poggi, R., additional, Riguzzi, P., additional, Rinaldi, R., additional, Rizzi, S., additional, Romeo, G., additional, Spagnolli, F., additional, Tinuper, P., additional, Trocino, C., additional, Dall'Agata, M., additional, Frattarelli, M., additional, Gentili, G., additional, Giovannini, A., additional, Iorio, P., additional, Pasquini, U., additional, Galletti, G., additional, Guidi, C., additional, Neri, W., additional, Patuelli, A., additional, Strumia, S., additional, Faedi, M., additional, Casmiro, M., additional, Gamboni, A., additional, Rasi, F., additional, Cruciani, G., additional, Cenni, P., additional, Dazzi, C., additional, Guidi, A.R., additional, Zumaglini, F., additional, Amadori, A., additional, Pasini, G., additional, Pasquinelli, M., additional, Pasquini, E., additional, Polselli, A., additional, Ravasio, A., additional, Viti, B., additional, Sintini, M., additional, Ariatti, A., additional, Bertolini, F., additional, Bigliardi, G., additional, Carpeggiani, P., additional, Cavalleri, F., additional, Meletti, S., additional, Nichelli, P., additional, Pettorelli, E., additional, Pinna, G., additional, Zunarelli, E., additional, Artioli, F., additional, Bernardini, I., additional, Costa, M., additional, Greco, G., additional, Guerzoni, R., additional, Stucchi, C., additional, Iaccarino, C., additional, Ragazzi, M., additional, Rizzi, R., additional, Zuccoli, G., additional, Api, P., additional, Cartei, F., additional, Colella, M., additional, Fallica, E., additional, Farneti, M., additional, Frassoldati, A., additional, Granieri, E., additional, Latini, F., additional, Monetti, C., additional, Saletti, A., additional, Schivalocchi, R., additional, Sarubbo, S., additional, Seraceni, S., additional, Tola, M.R., additional, Urbini, B., additional, Zini, G., additional, Giorgi, C., additional, Montanari, E., additional, Cerasti, D., additional, Crafa, P., additional, Dascola, I., additional, Florindo, I., additional, Giombelli, E., additional, Mazza, S., additional, Ramponi, V., additional, Servadei, F., additional, Silini, E.M., additional, Torelli, P., additional, Immovilli, P., additional, Morelli, N., additional, Vanzo, C., additional, and Nobile, C., additional

Published
2018
Full Text
View/download PDF

67. Experience of an information aid for newly diagnosed multiple sclerosis patients: A qualitative study on the SIMS-Trial

Author

Borreani, Claudia, Giordano, Andrea, Falautano, Monica, Lugaresi, Alessandra, Martinelli, Vittorio, Granella, Franco, Tortorella, Carla, Plasmati, Imma, Radaelli, Marta, Farina, Deborah, Dalla Bella, Eleonora, Bianchi, Elisabetta, Acquarone, Nicola, Miccinesi, Guido, Solari, Alessandra, D'Alessandro, R., Pucci, E., Uccelli, M. M., Trojano, M., Heesen, C., Mancardi, G. L., Milanese, C., Calabrese, D., Ferrari, G., Mattarozzi, K., Confalonieri, P., Antozzi, C., Maggi, L., Mantegazza, R., Martinelli, V., Colombo, B., Esposito, F., Moiola, L., Rodegher, M., Immovilli, P., De Luca, Giovanna, Di Tommaso, V., Di Ioia, M., Travaglini, D., Pietrolongo, E., Zimatore, G., Borreani, Claudia, Giordano, Andrea, Falautano, Monica, Lugaresi, Alessandra, Martinelli, Vittorio, Granella, Franco, Tortorella, Carla, Plasmati, Imma, Radaelli, Marta, Farina, Deborah, Dalla Bella, Eleonora, Bianchi, Elisabetta, Acquarone, Nicola, Miccinesi, Guido, Solari, Alessandra, D'Alessandro, R., Pucci, E., Uccelli, M. M., Trojano, M., Heesen, C., Mancardi, G. L., Milanese, C., Calabrese, D., Ferrari, G., Mattarozzi, K., Confalonieri, P., Antozzi, C., Maggi, L., Mantegazza, R., Martinelli, V., Colombo, B., Esposito, F., Moiola, L., Rodegher, M., Immovilli, P., De Luca, Giovanna, Di Tommaso, V., Di Ioia, M., Travaglini, D., Pietrolongo, E., and Zimatore, G.

Subjects
Adult, Male, Clinical Trials as Topic, Patient, Time Factor, Public Health, Environmental and Occupational Health, Middle Aged, Diagnosis communication, Complex intervention, Patient Education as Topic, Physician, Multiple Sclerosi, Female, Qualitative study, Shared decision making, Qualitative Research, Human
Abstract

Background The SIMS-Trial (ISRCTN81072971) proved the effectiveness, in terms of patient's knowledge and care satisfaction, of an add-on information aid (personal interview with a physician using a navigable CD and take-home booklet) in 120 newly diagnosed patients with multiple sclerosis (MS) from five Italian centres. Objective To scrutinize the experience of SIMS-Trial participants in order to gain better understanding of the effectiveness of the information aid and its components. Design We performed (i) nine individual semi-structured interviews with a purposeful sample of SIMS-Trial patients who received the information aid, (ii) focus group meeting (FGM) with the physicians who conducted the personal interview, and (iii) FGM with patients' caring neurologists. Results Patients' experience with the information aid was positive as it enhanced their understanding of their disease, being viewed as a guided tour of their medical condition. The physicians who conducted the personal interviews were also positive in their overall evaluation but noted an initial difficulty in using the CD. The caring neurologists had limited direct experience of the aid, and their views were confined to utility of the information aid in general. All participants considered the combination of personal interview, CD navigation and take-home booklet essential, but urged a more flexible scheduling of the personal interview. It also emerged that some content required revision and that the aid was unsuitable for patients with primary progressive MS. Conclusions The results of the study further support the value of the aid and also provide important indications for improving it and refining indications for use. © 2011 John Wiley & Sons Ltd.

Published
2014

68. Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis

Author

Rizzo, Roberta, Pietrobon, Silvia, Mazzoni, Elisa, Bortolotti, D., Martini, Fernanda, Castellazzi, Massimiliano, Casetta, Ilaria, Fainardi, Enrico, Luca, Dario, Granieri, Enrico, Tognon, Mauro, Granieri, E., Castellazzi, M., Casetta, I., Tola, M. R., Fainardi, E., Dallocchio, F., Bellini, T., Rizzo, R., Rotola, A., Di Luca, D., Seraceni, S., Contini, C., Sabbioni, S., Negrini, M., Tognon, M., Antonelli, T., Groppo, E., Gentile, M., Baldi, E., Caniatti, M. L., Ceruti, S., Manfrinato, M. R., Trentini, A., Miotto, E., Ferracin, M., Mazzoni, E., Pietrobon, S., Masini, I., Rotondo, J. C., Martini, F., Baruzzi, A., Roberto D'Alessandro, R., Michelucci, R., Salvi, F., Stecchi, S., Scandellari, C., Terzano, G., Granella, F., Nichelli, Paolo Frigio, Sola, P., Ferraro, Diana, Vitetta, F., Simone, ANNA MARIA, Bedin, Roberta, Marcello, N., Motti, L., Montepietra, S., Guidetti, D., Immovilli, P., Montanari, E., Pesci, I., Guareschi, A., Greco, G., Santangelo, M., Mauro, A. M., Malagù, S., Rasi, F., Spadoni, M., Galeotti, M., Fiorani, L., Neri, W., Ravasio, A., Pasquinelli, M., Gutman, S., and Monaldini, C.

Subjects
0301 basic medicine, Adult, Male, viruses, HLA-G, Socio-culturale, Multiple sclerosis, SV40, Medicine (all), Biochemistry, Genetics and Molecular Biology (all), Disease, Human leukocyte antigen, Simian virus 40, Antibodies, Viral, General Biochemistry, Genetics and Molecular Biology, Immunoglobulin G, Virus, 03 medical and health sciences, 0302 clinical medicine, Antigen, Aged, Antigens, Viral, Female, HLA-G Antigens, Humans, Inflammation, Middle Aged, Multiple Sclerosis, Solubility, medicine, Medicine(all), biology, business.industry, Biochemistry, Genetics and Molecular Biology(all), Research, General Medicine, medicine.disease, 030104 developmental biology, Immunology, biology.protein, business, 030217 neurology & neurosurgery
Abstract

Background Many investigators detected the simian polyomavirus SV40 footprints in human brain tumors and neurologic diseases and recently it has been indicated that SV40 seems to be associated with multiple sclerosis (MS) disease. Interestingly, SV40 interacts with human leukocyte antigen (HLA) class I molecules for cell entry. HLA class I antigens, in particular non-classical HLA-G molecules, characterized by an immune-regulatory function, are involved in MS disease, and the levels of these molecules are modified according with the disease status. Objective We investigated in serum samples, from Italian patients affected by MS, other inflammatory diseases (OIND), non-inflammatory neurological diseases (NIND) and healthy subjects (HS), SV40-antibody and soluble sHLA-G and the association between SV40-prevalence and sHLA-G levels. Methods ELISA tests were used for SV40-antibodies detection and sHLA-G quantitation in serum samples. Results The presence of SV40 antibodies was observed in 6 % of patients affected by MS (N = 4/63), 10 % of OIND (N = 8/77) and 15 % of NIND (N = 9/59), which is suggestive of a lower prevalence in respect to HS (22 %, N = 18/83). MS patients are characterized by higher sHLA-G serum levels (13.9 ± 0.9 ng/ml; mean ± St. Error) in comparison with OIND (6.7 ± 0.8 ng/ml), NIND (2.9 ± 0.4 ng/ml) and HS (2.6 ± 0.7 ng/ml) subjects. Interestingly, we observed an inverse correlation between SV40 antibody prevalence and sHLA-G serum levels in MS patients. Conclusion The data obtained showed a low prevalence of SV40 antibodies in MS patients. These results seems to be due to a generalized status of inability to counteract SV40 infection via antibody production. In particular, we hypothesize that SV40 immune-inhibitory direct effect and the presence of high levels of the immune-inhibitory HLA-G molecules could co-operate in impairing B lymphocyte activation towards SV40 specific peptides.

Published
2016

69. The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients

Author

Giordano, A, Uccelli, Mm, Pucci, E, Martinelli, V, Borreani, C, Lugaresi, A, Trojano, M, Granella, F, Confalonieri, P, Radice, D, Solari, A, D'Alessandro, R, Heesen, C, Mancardi, Gl, Milanese, C, Galimberti, S, Calabrese, D, Ferrari, G, Mattarozzi, K, Antozzi, C, Lauria, G, La Mantia, L, Pedotti, R, Mantegazza, R, Maggi, L, Colombo, B, Esposito, F, Moiola, L, Rodegher, M, Radaelli, M, Immovilli, P, Dalla Bella, E, De Luca, G, Mattoscio, M, Di Ioia, M, Pace, M, Travaglini, D, Maruotti, V, Farina, D, Zimatore, G, Plasmati, I, Tortorella, C., Giordano A., Uccelli M.M., Pucci E., Martinelli V., Borreani C., Lugaresi A., Trojano M., Granella F., Confalonieri P., Radice D., Solari A., D'Alessandro R., Heesen C., Mancardi G.L., Milanese C., Galimberti S., Calabrese D., Ferrari G., Mattarozzi K., Antozzi C., Lauria G., La Mantia L., Pedotti R., Mantegazza R., Maggi L., Colombo B., Esposito F., Moiola L., Rodegher M., Radaelli M., Immovilli P., Dalla Bella E., De Luca G., Mattoscio M., Di Ioia M., Pace M., Travaglini D., Maruotti V., Farina D., Zimatore G., Plasmati I., Tortorella C., (SIMS-Trial group)., Giordano, A., Uccelli, M. M., Pucci, E., Martinelli, V., Borreani, C., Lugaresi, A., Trojano, M., Granella, F., Confalonieri, P., Radice, D., Solari, A., D'Alessandro, R., Heesen, C., Mancardi, G. L., Milanese, C., Galimberti, S., Calabrese, D., Ferrari, G., Mattarozzi, K., Antozzi, C., Lauria, G., La Mantia, L., Pedotti, R., Mantegazza, R., Maggi, L., Colombo, B., Esposito, F., Moiola, L., Rodegher, M., Radaelli, M., Immovilli, P., Dalla Bella, E., De Luca, G., Mattoscio, M., Di Ioia, M., Pace, M., Travaglini, D., Maruotti, V., Farina, D., Zimatore, G., Plasmati, I., and Tortorella, C.

Subjects
Questionnaires, Male, law.invention, Disability Evaluation, Randomized controlled trial, Informed consent, law, Surveys and Questionnaires, Multiple Sclerosi, Content validity, Surveys and Questionnaire, Medicine, Young adult, Patient-reported outcome, Informed Consent, Psychiatric Status Rating Scale, Middle Aged, Newly diagnosed, Test (assessment), Knowledge, Neurology, Italy, drug therapy/psychology, Female, Human, Adult, Employment, medicine.medical_specialty, Multiple Sclerosis, Logistic Model, Adolescent, multiple sclerosis, questionnaire, MEDLINE, Reproducibility of Result, Education, Young Adult, Patient Education as Topic, Adolescent, Adult, Disability Evaluation, Education, Employment, Female, Humans, Informed Consent, Italy, Logistic Models, Male, Middle Aged, Multiple Sclerosis, drug therapy/psychology, Patient Education as Topic, Psychiatric Status Rating Scales, Questionnaires, Reproducibility of Results, Young Adult, Humans, Psychiatric Status Rating Scales, Questionnaire, business.industry, Construct validity, Reproducibility of Results, Surgery, Clinical trial, Logistic Models, Measurement development, Physical therapy, Neurology (clinical), business
Abstract

There are few studies on patient knowledge in multiple sclerosis (MS), and only two published questionnaires. The objective of this article was to develop and validate the MS Knowledge Questionnaire (MSKQ), a self-assessed instrument for newly diagnosed MS patients. Thirty multiple-choice statements, conceived to test MS knowledge, were produced by a multidisciplinary panel and pre-tested on three MS patients, resulting in an intermediate 26-item version. This was tested on 54 MS patients for internal consistency, content and construct validity (validation sample I). The final (25-item) MSKQ was a primary outcome measure in the SIMS-Trial on an information aid to newly diagnosed MS patients. Postal responses of SIMS-Trial participants to the MSKQ a month after intervention (validation sample II) were analysed. Median MSKQ scores in validation samples I and II were, respectively, 18 (range 9—23) and 17 (range 3—24). Acceptability, internal consistency (Kuder—Richardson-20 formula 0.76) and content validity were good. Educational attainment and receiving the information aid were the main independent predictors of MS knowledge. Other predictors were female sex (positive association) and disease duration (negative association). In conclusion, the MSKQ has good clinimetric properties and is sensitive to an educational intervention. We propose the MSKQ as a brief instrument for clinical practice and research.

Published
2009

70. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis

Author

Amato, M. P., Portaccio, E., Ghezzi, A., Hakiki, B., Zipoli, V., Martinelli, V., Moiola, L., Patti, F., La Mantia, L., Mancardi, G. L., Solaro, C., Tola, M. R., Pozzilli, C., De Giglio, L., Totaro, R., Lugaresi, A., Di Tommaso, V., Paolicelli, D., Marrosu, M. G., Comi, G., Pellegrini, F., Trojano, M., Siracusa, G., Rizzo, A., Zaffaroni, M., Radaelli, M., Milanese, C., Protti, A., Spreafico, C., Marazzi, R., Cavalla, P., Masera, S., Bergamaschi, R., Capello, E., Molinari, F., Caniatti, L., Granella, F., Immovilli, P., Annunziata, P., De Santi, L., Plewnia, K., Guidi, L., Bartolozzi, M. L., Mazzoni, M., De Luca, Giovanna, Carrozzo, A., D'Onghia, M., Musu, L., Cavallaro, T., Amato, M. P., Portaccio, E., Ghezzi, A., Hakiki, B., Zipoli, V., Martinelli, V., Moiola, L., Patti, F., La Mantia, L., Mancardi, G. L., Solaro, C., Tola, M. R., Pozzilli, C., De Giglio, L., Totaro, R., Lugaresi, A., Di Tommaso, V., Paolicelli, D., Marrosu, M. G., Comi, G., Pellegrini, F., Trojano, M., Siracusa, G., Rizzo, A., Zaffaroni, M., Radaelli, M., Milanese, C., Protti, A., Spreafico, C., Marazzi, R., Cavalla, P., Masera, S., Bergamaschi, R., Capello, E., Molinari, F., Caniatti, L., Granella, F., Immovilli, P., Annunziata, P., De Santi, L., Plewnia, K., Guidi, L., Bartolozzi, M. L., Mazzoni, M., De Luca, Giovanna, Carrozzo, A., D'Onghia, M., Musu, L., Cavallaro, T., and DIPARTIMENTO DI SCIENZE BIOMEDICHE E NEUROMOTORIE

Subjects
Adult, Male, medicine.medical_specialty, Multiple Sclerosis, Fetal Disease, Abortion, Follow-Up Studie, Cohort Studies, Pregnancy, Multiple Sclerosi, medicine, Abortion, Spontaneou, Humans, Prospective Studies, Fetus, treatment, business.industry, Obstetrics, multiple sclerosis, treatment, pregnancy, interferon, Infant, Newborn, Pregnancy Outcome, interferon, Odds ratio, Interferon-beta, medicine.disease, Confidence interval, Surgery, Abortion, Spontaneous, Fetal Diseases, Prospective Studie, Fetal Weight, In utero, Propensity score matching, Female, Neurology (clinical), Cohort Studie, business, Cohort study, Follow-Up Studies, Human
Abstract

none 23 no Objective: To assess pregnancy and fetal outcomes after in utero exposure to interferon-beta (IFN beta) in all pregnancies occurring in women with multiple sclerosis (MS) during the study period, with a specific focus on the risk of spontaneous abortion. Methods: In this cohort study, data were gathered through a standardized, semi-structured interview. Patients who discontinued IFN beta less than 4 weeks from conception (exposed) were compared with those who had discontinued the drug at least 4 weeks from conception or who were never treated (not exposed). Possible confounders were handled through multivariate analyses adjusted for propensity score (PS). Results: We collected data on 396 pregnancies in 388 women, 88 classified as exposed (mean exposure 4.6 +/- 5.8 weeks). IFN beta exposure was not associated with an increased risk of spontaneous abortion (PS-adjusted odds ratio [OR] 1.08, 95% confidence interval [CI] 0.4 to 2.9, p = 0.88), although it was associated with both lower baby weight (PS-adjusted beta -113.8, p < 0.0001) and length (PS-adjusted beta -1.102, p < 0.0001). Proportion of spontaneous abortion in exposed patients fell within the range expected for the Italian population in the same period. IFN beta exposure (PS-adjusted OR 2.11, 95% CI 1.18 to 3.78, p = 0.012) and cesarean delivery were the only predictors of preterm delivery. In the exposed group, we did not observe any significant fetal complications, malformations, or developmental abnormalities over a median follow-up of 2.1 years. Conclusions: Our findings point to the relative safety of IFN beta exposure times of up to 4 weeks and can assist neurologists facing therapeutic decisions in women with MS with a pregnancy plan. Neurology (R) 2010;75:1794-1802 none Amato MP; Portaccio E; Ghezzi A; Hakiki B; Zipoli V; Martinelli V; Moiola L; Patti F; La Mantia L; Mancardi GL; Solaro C; Tola MR; Pozzilli C; De Giglio L; Totaro R; Lugaresi A; Di Tommaso V; Paolicelli D; Marrosu MG; Comi G; Pellegrini F; Trojano M MS Study Group of the Italian Neurological Society; De Luca G Amato MP; Portaccio E; Ghezzi A; Hakiki B; Zipoli V; Martinelli V; Moiola L; Patti F; La Mantia L; Mancardi GL; Solaro C; Tola MR; Pozzilli C; De Giglio L; Totaro R; Lugaresi A; Di Tommaso V; Paolicelli D; Marrosu MG; Comi G; Pellegrini F; Trojano M MS Study Group of the Italian Neurological Society; De Luca G

Published
2010

71. Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial

Author

Borreani, C, Giordano, A, Falautano, M, Lugaresi, A, Martinelli, V, Granella, F, Tortorella, C, Plasmati, I, Radaelli, M, Dalla Bella, E, Bianchi, E, Acquarone, N, Miccinesi, G, Solari, A, D' Alessandro, R, Pucci, E, Uccelli, Mm, Trojano, M, Heesen, C, Mancardi, Gl, Milanese, C, Calabrese, D, Ferrari, G, Mattarozzi, K, Confalonieri, P, Antozzi, C, Maggi, L, Mantegazza, R, Colombo, B, Esposito, F, Moiola, L, Rodegher, M, Immovilli, P, Farina, D, De Luca, G, Di Tommaso, V, Di Ioia, M, Travaglini, D, Pietrolongo, E, and Zimatore, G.

Subjects
Adult, Male, Clinical Trials as Topic, Multiple Sclerosis, Time Factors, Patient Education as Topic, Patients, Physicians, Humans, Female, Middle Aged, Original Research Papers, Qualitative Research
Abstract

The SIMS-Trial (ISRCTN81072971) proved the effectiveness, in terms of patient's knowledge and care satisfaction, of an add-on information aid (personal interview with a physician using a navigable CD and take-home booklet) in 120 newly diagnosed patients with multiple sclerosis (MS) from five Italian centres.To scrutinize the experience of SIMS-Trial participants in order to gain better understanding of the effectiveness of the information aid and its components.We performed (i) nine individual semi-structured interviews with a purposeful sample of SIMS-Trial patients who received the information aid, (ii) focus group meeting (FGM) with the physicians who conducted the personal interview, and (iii) FGM with patients' caring neurologists.Patients' experience with the information aid was positive as it enhanced their understanding of their disease, being viewed as a guided tour of their medical condition. The physicians who conducted the personal interviews were also positive in their overall evaluation but noted an initial difficulty in using the CD. The caring neurologists had limited direct experience of the aid, and their views were confined to utility of the information aid in general. All participants considered the combination of personal interview, CD navigation and take-home booklet essential, but urged a more flexible scheduling of the personal interview. It also emerged that some content required revision and that the aid was unsuitable for patients with primary progressive MS.The results of the study further support the value of the aid and also provide important indications for improving it and refining indications for use.

Published
2014

73. Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial

Author

Giordano A, Martinelli V, Lugaresi A, Pucci E, Granella F, Trojano M, Solari A, Messmer Uccelli M, Ferrari G, Martini F, Radice D, D'Annunzio G, Farina D, Travaglini D, Pietrolongo E, Onofrj M, Torri Clerici V, Bonanno S, Brambilla L, Confalonieri P, Radaelli M, Messina J, Comi G, Tortorella C, Luciannatelli E, Senesi C, Tsantes E, Conti M, Rottoli M, Bellantonio P, Fischetti M, Fantozzi R, Pala A, Traccis S, Di Battista G, Bianchi M, Benedetti M, Gaetani L, Di Filippo M, Carolei A, Totaro R, Lanzillo R, Brescia Morra V, Coppola R, Cottone S, Chiavazza C, Cavalla P, Leonardi C, Aguglia U, Ziuliani C, Valla P, Sasanelli F, Valentino P, Quattrone A, Martino PG, Russo M, Vita G, Immovilli P., Giordano A, Lugaresi A, Confalonieri P, Granella F, Radice D, Trojano M, Martinelli V, Solari A, on behalf of the SIMS-Practice groupa, Giordano, A, Lugaresi, A, Confalonieri, P, Granella, F, Radice, D, Trojano, M, Comi, Giancarlo, on behalf of the SIMS Practice, Group, and Radaelli, Marta

Subjects
Adult, Male, medicine.medical_specialty, Health Knowledge, Attitudes, Practice, Multiple Sclerosis, Adolescent, patient satisfaction, Health literacy, Group B, law.invention, Interviews as Topic, Young Adult, Patient satisfaction, complex health intervention, Randomized controlled trial, Patient Education as Topic, law, Surveys and Questionnaires, Multiple Sclerosi, Clinical endpoint, Medicine, Humans, Prospective Studies, Young adult, Prospective cohort study, disease knowledge, information aid, Internet, business.industry, Multiple sclerosis, multiple sclerosis, clinical practice, Middle Aged, medicine.disease, Health Literacy, Treatment Outcome, Neurology, Italy, Physical therapy, Female, Pamphlets, Neurology (clinical), business, Comprehension
Abstract

Background: The SIMS-Trial showed that the ‘Sapere Migliora’ information aid (IA) for newly diagnosed people with multiple sclerosis (PwMS) effectively improved patient knowledge and satisfaction with care. Objectives: The objectives of this paper are to assess the effectiveness of the IA in clinical practice and to compare the whole IA with the take-home booklet/website component alone. Methods: After updating the IA and replacing the CD with a website, a prospective, open-label non-randomised controlled trial compared the whole IA (group A, five SIMS-Trial centres) to take-home (group B, 16 centres). One month after the intervention, participants completed the MS Knowledge Questionnaire (MSKQ), care satisfaction questionnaire (COSM-R) (primary study outcomes), Hospital and Anxiety Depression Scale, and ad hoc questionnaire appraising the IA. Results: We enrolled 159 newly diagnosed PwMS (May 2012–March 2013). Drop-outs were four of 77 (5%, group A) and 11/82 (13%, group B). Primary endpoint (highest tertile both for MSKQ and COSM-R section 2 scores) was achieved by 38/77 (49%) group A and 33/82 (40%) group B ( p = 0.25). Attainment of secondary outcomes was also similar between groups. Conclusions: This study shows that the entire IA is not superior to the booklet/website alone, and that both are comparable in efficacy to the intervention arm of the SIMS-Trial. Trial registration number: ISRCTN78940214.

Published
2014

74. Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial

Author

Giordano, A, Lugaresi, A, Confalonieri, P, Granella, F, Radice, D, Trojano, M, Martinelli, V, Pucci E, Solari A., Messmer Uccelli, M, Ferrari, G, Martini, F, D'Annunzio, G, Farina, D, Travaglini, D, Pietrolongo, E, Onofrj, M, Torri Clerici, V, Bonanno, S, Brambilla, L, Radaelli, M, Messina, J, Comi, G, Tortorella, C, Luciannatelli, E, Senesi, C, Tsantes, E, Conti, M, Rottoli, M, Bellantonio, P, Fischetti, M, Fantozzi, R, Pala, A, Traccis, S, Di Battista, G, Bianchi, M, Benedetti, M, Gaetani, L, Di Filippo, M, Carolei, A, Totaro, R, Lanzillo, R, Brescia Morra, V, Coppola, R, Cottone, S, Chiavazza, C, Cavalla, P, Leonardi, C, Aguglia, U, Ziuliani, C, Valla, P, Sasanelli, F, Valentino, P, Quattrone, A, Martino, Pg, Russo, M, Vita, Giuseppe, and Immovilli, P.

Subjects
Multiple sclerosis, complex health intervention, Multiple sclerosis, complex health intervention, information aid, disease knowledge, patient satisfaction, clinical practice, patient satisfaction, disease knowledge, information aid, clinical practice
Published
2014

75. Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III

Author

Visani, M, de Biase, D, Marucci, G, Cerasoli, S, Nigrisoli, E, Bacchi Reggiani ML, Albani, F, Baruzzi, A, Pession, A, Calbucci, F, D'Alessandro, R, Michelucci, R, Brandes, A, Eusebi, V, Ceruti, S, Fainardi, E, Tamarozzi, R, Emiliani, E, Cavallo, M, Franceschi, E, Tosoni, A, Fiorica, F, Valentini, A, Depenni, R, Mucciarini, C, Crisi, G, Sasso, E, Biasini, C, Cavanna, L, Guidetti, D, Marcello, N, Pisanello, A, Cremonini, Am, Guiducci, G, Agati, R, Ambrosetto, G, Bacci, A, Baldin, E, Baldrati, A, Barbieri, E, Bartolini, S, Bellavista, E, Bisulli, F, Bonora, E, Bunkheila, F, Carelli, V, Crisci, M, Dall'Occa, P, Ferro, S, Franceschi, C, Frezza, G, Grasso, V, Leonardi, M, Morandi, L, Mostacci, B, Palandri, G, Pasini, E, Pastore Trossello, M, Poggi, R, Riguzzi, P, Rinaldi, R, Rizzi, S, Romeo, G, Spagnolli, F, Tinuper, P, Trocino, C, Dall'Agata, M, Frattarelli, M, Gentili, G, Giovannini, A, Iorio, P, Pasquini, U, Galletti, G, Guidi, C, Neri, W, Patuelli, A, Strumia, S, Faedi, M, Casmiro, M, Gamboni, A, Rasi, F, Cruciani, G, Cenni, P, Dazzi, C, Guidi, Ar, Zumaglini, F, Amadori, A, Pasini, G, Pasquinelli, M, Pasquini, E, Polselli, A, Ravasio, A, Viti, B, Sintini, M, Ariatti, A, Bertolini, F, Bigliardi, G, Carpeggiani, P, Cavalleri, F, Meletti, S, Nichelli, P, Pettorelli, E, Pinna, G, Zunarelli, E, Artioli, F, Bernardini, I, Costa, M, Greco, G, Guerzoni, R, Stucchi, C, Iaccarino, C, Ragazzi, M, Rizzi, R, Zuccoli, G, Api, P, Cartei, F, Fallica, E, Granieri, E, Latini, F, Lelli, G, Monetti, C, Saletti, A, Schivalocchi, R, Seraceni, S, Tola, Mr, Urbini, B, Giorgi, C, Montanari, E, Cerasti, D, Crafa, P, Dascola, I, Florindo, I, Giombelli, E, Mazza, S, Ramponi, V, Servadei, F, Silini, Em, Torelli, P, Immovilli, P, Morelli, N, Vanzo, C, Nobile, C, Michela Visani, Dario de Biase, Gianluca Marucci, Serenella Cerasoli, Evandro Nigrisoli, Maria Letizia Bacchi Reggiani, Fiorenzo Albani, Agostino Baruzzi, Annalisa Pession, the PERNO study group [, Elena Bonora, and ]

Subjects
Adult, Male, Cancer Research, Low-grade brain tumor, Brain neoplasia, Glioblastoma, Low-grade brain tumors, MicroRNA, Real-time PCR, Aged, Brain Neoplasms, Female, Gene Expression Profiling, Humans, MicroRNAs, Middle Aged, Neoplasm Grading, RNA, Neoplasm, Gene Expression Regulation, Neoplastic, Genetics, Molecular Medicine, Biology, Bioinformatics, medicine.disease_cause, NO, Brain Neoplasm, Genetic, microRNA, medicine, Locked nucleic acid, MicroRNA, Glioblastoma, Brain neoplasia, Low-grade brain tumors, Real-time PCR, Cancer, General Medicine, medicine.disease, Molecular medicine, Fold change, Gene expression profiling, Real-time polymerase chain reaction, Oncology, Cancer research, Carcinogenesis, Corrigendum, Human
Abstract

Several biomarkers have been proposed as useful parameters to better specify the prognosis or to delineate new target therapy strategies for glioblastoma patients. MicroRNAs could represent putative target molecules, considering their role in tumorigenesis, cancer progression and their specific tissue expression. Although several studies have tried to identify microRNA signature for glioblastoma, a microRNA profile is still far from being well-defined. In this work the expression of 19 microRNAs (miR-7, miR-9, miR-9∗, miR-10a, miR-10b, miR-17, miR-20a, miR-21, miR-26a, miR-27a, miR-31, miR-34a, miR-101, miR-137, miR-182, miR-221, miR-222, miR-330, miR-519d) was evaluated in sixty formalin-fixed and paraffin-embedded glioblastoma samples using a locked nucleic acid real-time PCR. Moreover, a comparison of miRNA expressions was performed between primary brain neoplasias of different grades (grades IV-I). The analysis of 14 validated miRNA expression in the 60 glioblastomas, using three different non-neoplastic references as controls, revealed a putative miRNA signature: mir-10b and miR-21 were up-regulated, while miR-7, miR-31, miR-101, miR-137, miR-222 and miR-330 were down-regulated in glioblastomas. Comparing miRNA expression between glioblastoma group and gliomas of grades I-III, 3 miRNAs (miR-10b, mir-34a and miR-101) showed different regulation statuses between high-grade and low-grade tumors. miR-10b was up-regulated in high grade and significantly down-regulated in low-grade gliomas, suggesting that could be a candidate for a GBM target therapy. This study provides further data for the identification of a miRNA profile for glioblastoma and suggests that different-grade neoplasia could be characterized by different expression of specific miRNAs.

Published
2014

77. Erratum to: Survival prediction in high-grade gliomas using CT perfusion imaging

Author

Yeung, Tp, Wang, Y, He, W, Urbini, B, Gafà, R, Ulazzi, L, Yartsev, S, Bauman, G, Lee TY, Fainardi, E, Project of Emilia-Romagna Region on Neuro-Oncology (PERNO) Study Group Participants :Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall’Occa, P., de Biase, D., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Marucci, G., Morandi, L., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Pession, A., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., (Bologna), Trocino C., Dall’Agata, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., (Forlı`-Cesena), Strumia S., Faedi, M., (IRCCS Istituto Scientifico Romagnolo per lo Studio, e la Cura dei Tumori), Casmiro, M., Gamboni, A., Rasi, F. (Faenza R. A. )., (Lugo, Cruciani G., RA), Cenni, P., Dazzi, C., Guidi, A. R., (Ravenna), Zumaglini F., Amadori, A., Pasini, G., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., (Rimini), Viti B., (Cattolica, Sintini M., RN), Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., (Modena), Zunarelli E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C. (Carpi M. O. )., Iaccarino, C, Ragazzi, M., Rizzi, R., (Istituto di Ricovero e Cura a Carattere Scientifico, Zuccoli G., Reggio, Emilia), Api, P., Cartei, F., Colella, M., Fallica, E., Farneti, M., Frassoldati, A., Granieri, E., Latini, F., Monetti, C., Saletti, A., Schivalocchi, R., Sarubbo, S., Seraceni, S., Tola, M. R., Urbini, B., (Ferrara), Zini G., Giorgi, C., Montanari, E. (Fidenza P. R. )., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, Em., (Parma), Torelli P., Immovilli, P., Morelli, N., (Piacenza), Vanzo C., and Nobile, C. (Padova).

Subjects
Cancer Research, medicine.medical_specialty, Neuroradiology unit, Neurology, Oncology, business.industry, General surgery, Medicine, Neurology (clinical), business
Abstract

Baruzzi A. (Chair), Albani F., Calbucci F., D’Alessandro R., Michelucci R. (IRCCS Institute of Neurological Sciences, Bologna, Italy), Brandes A. (Department of Medical Oncology, Bellaria-Maggiore Hospitals, Bologna, Italy), Eusebi V. (Department of Hematology and Oncological Sciences ‘‘L. & A. Seragnoli’’, Section of Anatomic Pathology at Bellaria Hospital, Bologna, Italy), Ceruti S., Fainardi E., Tamarozzi R. (Neuroradiology Unit, Department of Neurosciences and Rehabilitation, S. Anna Hospital, Ferrara, Italy), Emiliani E. (Istituto Oncologico Romagnolo, Department of Medical Oncology, Santa Maria delle Croci Hospital, Ravenna, Italy), Cavallo M. (Division of Neurosurgery, Department of Neurosciences and Rehabilitation, S. Anna Hospital, Ferrara, Italy).

Published
2015

78. Definition of miRNAs Expression Profile in Glioblastoma Samples: The Relevance of Non-Neoplastic Brain Reference

Author

Visani, Michela, De Biase, Dario, Marucci, Gianluca, Taccioli, Cristian, Baruzzi, Agostino, Pession, Annalisa, Baruzzi, A., Albani, F., Calbucci, F., D'alessandro, R., Michelucci, R., Brandes, A., Eusebieusebi, V., Ceruti, S., Fainardi, E., Tamarozzi, R., Emiliani, E., Cavallo, M., Franceschi, E., Tosoni, A., Fiorica, F., Valentini, A., Depenni, R., Mucciarini, C., Crisi, G., Sasso, E., Biasini, C., Cavanna, L., Guidetti, D., Marcello, N., Pisanello, A., Cremonini, A. M., Guiducci, G., De Pasqua, S., Testoni, S., Agati, R., Ambrosetto, G., Bacci, A., Baldin, E., Baldrati, A., Barbieri, E., Bartolini, S., Bellavista, E., Bisulli, F., Bonora, E., Bunkheila, F., Carelli, V., Crisci, M., Dall'occa, P., Ferro, S., Franceschi, C., Frezza, G., Grasso, V., Leonardi, M., Mostacci, B., Palandri, G., Pasini, E., Pastore Trossello, M., Poggi, R., Riguzzi, P., Rinaldi, R., Rizzi, S., Romeo, G., Spagnolli, F., Tinuper, P., Trocino, C., Cerasoli, S., Dall'agata, M., Faedi, M., Frattarelli, M., Gentili, G., Giovannini, A., Iorio, P., Pasquini, U., Galletti, G., Guidi, C., Neri, W., Patuelli, A., Strumia, S., Casmiro, M., Gamboni, A., Rasi, F., Cruciani, G., Cenni, P., Dazzi, C., Guidi, A. R., Zumaglini, F., Amadori, A., Pasini, G., Pasquinelli, M., Pasquini, E., Polselli, A., Ravasio, A., Viti, B., Sintini, M., Ariatti, A., Bertolini, F., Bigliardi, G., Carpeggiani, P., Cavalleri, F., Meletti, S., Nichelli, P., Pettorelli, E., Pinna, G., Zunarelli, E., Artioli, F., Bernardini, I., Costa, M., Greco, G., Guerzoni, R., Stucchi, C., Iaccarino, C., Ragazzi, M., Rizzi, R., Zuccoli, G., Api, P., Cartei, F., Fallica, E., Granieri, E., Latini, F., Lelli, G., Monetti, C., Saletti, A., Schivalocchi, R., Seraceni, S., Tola, M. R., Urbini, B., Giorgi, C., Montanari, E., Cerasti, D., Crafa, P., Dascola, I., Florindo, I., Giombelli, E., Mazza, S., Ramponi, V., Servadei, F., Silini, E. M., Torelli, P., Immovilli, P., Morelli, N., Vanzo, C., Nobile, C., M. Visani, D. de Biase, G. Marucci, C. Taccioli, A. Baruzzi, A. Pession, Perno Study Group, F. Albani, V. Eusebi, F. Bisulli, V. Carelli, M. Leonardi, B. Mostacci, P. Tinuper, the PERNO Study group [, E. Bonora, and ]

Subjects
Male, Genetics and Molecular Biology (all), Adult, Aged, Brain, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Glioblastoma, Humans, MicroRNAs, Middle Aged, Real-Time Polymerase Chain Reaction, Reference Values, Statistics, Nonparametric, Biochemistry, Genetics and Molecular Biology (all), Agricultural and Biological Sciences (all), Gene Expression, Bioinformatics, Biochemistry, Surgical oncology, Nucleic Acids, metabolism, Female, Gene Expression Profiling, Molecular Cell Biology, Basic Cancer Research, Gene expression, normal adjacent the tumor, Neurological Tumors, methods, Gene Expression Regulation, brain tumors, glioblastoma, miRNAs, Multidisciplinary, Cancer Risk Factors, Medicine (all), Statistics, non-neoplastic brain, Real-time polymerase chain reaction, Oncology, miRNAs, Medicine, DNA microarray, brain RNA commercial reference, Research Article, Adult, Aged, Brain, Neoplastic, genetics/physiology, Glioblastoma, metabolism, Humans, Male, MicroRNAs, metabolism, Middle Aged, Real-Time Polymerase Chain Reaction, Reference Values, Statistics, Nonparametric, Science, Brain tumor, Biology, NO, Molecular Genetics, epileptic tissue, Text mining, microRNA, medicine, miRNA, business.industry, Computational Biology, Cancers and Neoplasms, medicine.disease, Gene expression profiling, Gene Expression Regulation, Cancer research, RNA, brain tumors, metabolism, Middle Aged, Real-Time Polymerase Chain Reaction, Reference Values, Statistic, business, metabolism, Humans, Male, MicroRNA, Glioblastoma Multiforme
Abstract

Glioblastoma is the most aggressive brain tumor that may occur in adults. Regardless of the huge improvements in surgery and molecular therapy, the outcome of neoplasia remains poor. MicroRNAs are small molecules involved in several cellular processes, and their expression is altered in the vast majority of tumors. Several studies reported the expression of different miRNAs in glioblastoma, but one of the most critical point in understanding glioblastoma miRNAs profile is the comparison of these studies. In this paper, we focused our attention on the non-neoplastic references used for determining miRNAs expression. The aim of this study was to investigate if using three different non-neoplastic brain references (normal adjacent the tumor, commercial total RNA, and epileptic specimens) could provide discrepant results. The analysis of 19 miRNAs was performed using Real-Time PCR, starting from the set of samples described above and the expression values compared. Moreover, the three different normal RNAs were used to determine the miRNAs profile in 30 glioblastomas. The data showed that different non-neoplastic controls could lead to different results and emphasize the importance of comparing miRNAs profiles obtained using the same experimental condition.

Published
2013

79. Updating on Italian stroke units: the 'CCM study'

Author

Guidetti, D., Spallazzi, M., Toni, Danilo, Rota, E., Morelli, N., Immovilli, P., Baldereschi, M., Polizzi, B. M., Ferro, S., Inzitari, D., For The Promotion, and Stroke Care In Italy Project Working Group, Implementation O. F.

Subjects
Thrombolytic treatment, Legislation, Dermatology, stroke care, Stroke care, Logistic regression, acute wards, Surveys and Questionnaires, Health care, medicine, Humans, Thrombolytic Therapy, Stroke, stroke unit, Descriptive statistics, business.industry, Stroke units, General Medicine, medicine.disease, Psychiatry and Mental health, Italy, Tissue Plasminogen Activator, stroke, Neurology (clinical), Medical emergency, business, Hospital Units
Abstract

The Stroke Units (SUs) have been demonstrated to be efficient and cost effective for acute stroke care. Nevertheless, the level of stroke unit implementation in Italy does not correspond to expectations yet. This study is a survey, which aims at assessing the current status of in-hospital stroke care in the Italian regions and at updating SUs. The survey was conducted by means of a semi-structured questionnaire, based on 18 stroke care “quality indicators”, submitted to all the Italian centres that had taken part in the SITS-MOST study, and to other centres advised by the coordinator of SITS studies and by regional opinion leaders of stroke. SUs were defined as acute wards, with stroke-dedicated beds and dedicated teams that had been formally authorised to administer rt-PA. A statistical analysis was performed by a descriptive statistics and logistic regression model. The study was carried out from November 2009 to September 2010. A total of 168 forms were sent out and 153 replies received. Seven centres, which had not performed any thrombolytic treatment, and 16 which did not fulfil the criteria for the definition of SU were excluded from the study. Most of the centres reported more than 100 stroke patient admissions per year, i.e., 122 (84 %) from 100 to 500, 18 (12 %) more than 500. The 19 % of the centres admitted more than 30 % of patients within 3 h from the symptom onset and only 30 % admitted more than 30 % of patients within 4.5 h. The mean number of thrombolyses performed in the last 6 months was 10 for centres with a doctor on duty 24 h a day, 6 for those that have a doctor on duty from 8 a.m. to 8 p.m. and a doctor on call for night, and 5 for centres with a doctor on call 24 h a day. The territorial distribution of the SUs is remarkably heterogeneous: 87 SUs (67 %) are located in the North of Italy, 28 (22 %) in the central part of Italy and only 15 (11 %) in the South. The last few years have witnessed a rise in both the diffusion of SUs and access to thrombolytic therapy in Italy. Despite this, there are a few large areas, mostly in the south, where the requirements of healthcare legislation are not met, and access to a dedicated SU and thrombolytic treatment is still limited and poor.

Published
2012

81. Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis

Author

Solari, A, Mattarozzi, K, Vignatelli, L, Giordano, A, Russo, P, Messmeruccelli, M, D'Alessandro, R, Pucci, E, Martinelli, V, Uccelli, Mm, Borreani, C, Trojano, M, Heesen, C, Mancardi, Gl, Milanese, C, Galimberti, S, Calabrese, D, Ferrari, G, Confalonieri, P, Mantegazza, R, Maggi, L, Colombo, B, Esposito, F, Moiola, L, Rodegher, M, Radaelli, M, Granella, F, Immovilli, P, Dalla Bella, E, Lugaresi, A, De Luca, G, Mattoscio, M, Di Ioia, M, Travaglini, D, Farina, D, Zimatore, G, Plasmati, I, Tortorella, C, Orsolamalpighi, S, Guidolin, L, Leone, M, Motti, L, Tola, Mr, Montanari, E, Guareschi, A, Pesci, I, Pattini, M, Feo, C, Torricelli, L, Santangelo, M, Stecchi, S, Scandellari, C, Balugani, R, La Mola, L, Montagna, P, Pizza, F, Avoni, P, Baldin, E, Delaj, L, Rinaldi, R, Baldi, E, Caniatti, L, Milani, P, Mussuto, V, Manzoni, M, Casmiro, M, Fiorani, L, Galeotti, M, Guerrini, C, Neri, W, Mambelli, L, Malagù, S, Naldi, P, Calzoni, S, Collimedaglia, L, Pietrolongo, E, Di Tommaso, V, Pace, M, Benedetti, M, Rossi, F, Pastoretrossello, M, Faccioli, L, Spinardi, L., Solari A., Mattarozzi K., Vignatelli L., Giordano A., Russo P.M., Uccelli M.M., D'Alessandro R., Montagna P., Pizza F., Avoni P., Baldin E., Delaj L., SIMS-Trial group, and GERONIMUS group.

Subjects
Questionnaires, Adult, Male, medicine.medical_specialty, Neurology, Multiple Sclerosis, Psychometrics, Adolescent, Adolescent, Adult, Aged, Cognition, physiology, Communication, Disease Progression, Early Diagnosis, Factor Analysis, Statistical, Female, Humans, Male, Middle Aged, Multiple Sclerosis, psychology, Patient Satisfaction, Physician-Patient Relations, Psychiatric Status Rating Scales, Questionnaires, Reproducibility of Results, Young Adult, Newly diagnosed, psychology, Young Adult, Patient satisfaction, DIAGNOSIS COMMUNICATION, Cognition, Surveys and Questionnaires, medicine, Humans, Aged, Psychiatric Status Rating Scales, Physician-Patient Relations, PSYCHOMETRICS, business.industry, Multiple sclerosis, Communication, Reproducibility of Results, Statistical, Middle Aged, medicine.disease, Surgery, Clinical trial, Early Diagnosis, Patient Satisfaction, physiology, PATIENT-REPORTED OUTCOMES, Physical therapy, Disease Progression, Female, Neurology (clinical), business, Factor Analysis, Statistical, Factor Analysis
Abstract

Background: We describe the development and clinical validation of a patient self-administered tool assessing the quality of multiple sclerosis diagnosis disclosure. Method: A multiple sclerosis expert panel generated questionnaire items from the Doctor’s Interpersonal Skills Questionnaire, literature review, and interviews with neurology inpatients. The resulting 19-item Comunicazione medico-paziente nella Sclerosi Multipla (COSM) was pilot tested/debriefed on seven patients with multiple sclerosis and administered to 80 patients newly diagnosed with multiple sclerosis. The resulting revised 20-item version (COSM-R) was debriefed on five patients with multiple sclerosis, field tested/debriefed on multiple sclerosis patients, and field tested on 105 patients newly diagnosed with multiple sclerosis participating in a clinical trial on an information aid. The hypothesized monofactorial structure of COSM-R section 2 was tested on the latter two groups. Results: The questionnaire was well accepted. Scaling assumptions were satisfactory in terms of score distributions, item—total correlations and internal consistency. Factor analysis confirmed section 2’s monofactorial structure, which was also test—retest reliable (intraclass correlation coefficient [ICC] 0.73; 95% CI 0.54—0.85). Section 1 had only fair test—retest reliability (ICC 0.45; 95% CI 0.12—0.69), and three items had 8—21% missed responses. Conclusions: COSM-R is a brief, easy-to-interpret MS-specific questionnaire for use as a health care indicator.

Published
2010

83. Interferon Beta therapy and pregnancy outcomes in patients with multiple sclerosis

Author

Portaccio, E, Ghezzi, A, Rizzo, A, Zipoli, V, Hakiki, B, Pellegrini, F, De Giglio, L, Pozzilli, C, Fuiani, A, Trojano, M, Musu, L, Marrosu, M, Cavallaro, T, Patti, Francesco, Milanese, C, La Mantia, L, Capello, E, Mancardi, G, Spreafico, C, Protti, A, Marazzi, R, Immovilli, P, Granella, F, Caniatti, L, Antiga, E, Tola, M, Bartolozi, L, Guidi, L, Di Tommaso, V, Lugaresi, A, Martinelli, V, Comi, G, Amato, M, and MS Study Group of The Italian Neurological Society

Published
2008

84. Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH study.

Author

Patti, Francesco, Chisari, Clara Grazia, Toscano, Simona, Annovazzi, Pietro, Banfi, Paola, Bergamaschi, Roberto, Clerici, Raffaella, Conti, Marta Zaffira, Cortese, Antonio, Fantozzi, Roberta, Ferraro, Diana, Fischetti, Mariano, Frigo, Maura, Gatto, Maurizia, Immovilli, Paolo, Leoni, Stefania, Malucchi, Simona, Maniscalco, Giorgia, Marfia, Girolama Alessandra, and Paolicelli, Damiano

Abstract

• Cognitive profile and physician-based and patients-reported outcomes could have a considerable impact on the disease management and on treatment decision making. • According to the Control Preference Scale, more than 50% of patients who needed to change therapy chose a "collaborative" role in making treatment decision. • Cognitive profile with SDMT seems to influence patients' preference on treatment decision. Clinicians are increasingly recognizing the importance of shared decision-making in complex treatment choices, highlighting the importance of the patient's rationale and motivation for switching therapies. This study aimed to evaluate the association between different modalities of changing multiple sclerosis (MS) treatments, cognitive profile and attitude and preferences of patients concerning treatment choice. This multicenter cross-sectional study was conducted at 28 Italian MS centers in the period between June 2016 and June 2017. We screened all MS patients treated with any DMT, with a treatment compliance of at least 80% of therapy administered during the 3 last months who needed to modify MS therapy because of efficacy, safety or other reasons during a follow-up visit. At the time of switching the symbol digit modalities test (SDMT) and the Control Preference Scale (CPS) were evaluated. According to the CPS, patients were classified as "active" (i.e. who prefer making the medical decision themselves), "collaborative" (i.e. who prefer decisions be made jointly with the physician), or "passive" (i.e. who prefer the physician make the decision). Out of 13,657 patients recorded in the log, 409 (3%) changed therapy. Of these, 336 (2.5%) patients, 69.6% were female and with mean age 40.6 ± 10.5 years, were enrolled. According to the CPS score evaluation, a significant high percentage of patients (51.1%) were considered collaborative, 74 patients (22.5%) were passive, and 60 (18.2%) patients were active. Stratifying according to CPS results, we found a higher SDMT score among collaborative patients compared to active and passive ones (45.8 ± 12.3 versus 41.0 ± 13.2 versus 41.7 ± 12.8, p < 0.05). In this study, the CPS evaluation showed that more than 50% of patients who needed to change therapy chose a "collaborative" role in making treatment decision. Cognitive profile with SDMT seems to correlate with patients' preference on treatment decision, showing better scores in collaborative patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

86. Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?

Author

Brandes, Alba A., primary, Franceschi, Enrico, additional, Ermani, Mario, additional, Tosoni, Alicia, additional, Albani, Fiorenzo, additional, Depenni, Roberta, additional, Faedi, Marina, additional, Pisanello, Anna, additional, Crisi, Girolamo, additional, Urbini, Benedetta, additional, Dazzi, Claudio, additional, Cavanna, Luigi, additional, Mucciarini, Claudia, additional, Pasini, Giuseppe, additional, Bartolini, Stefania, additional, Marucci, Gianluca, additional, Morandi, Luca, additional, Zunarelli, Elena, additional, Cerasoli, Serenella, additional, Gardini, Giorgio, additional, Lanza, Giovanni, additional, Silini, Enrico Maria, additional, Cavuto, Silvio, additional, Baruzzi, Agostino, additional, Baruzzi, A., additional, Albani, F., additional, Calbucci, F., additional, D'Alessandro, R., additional, Michelucci, R., additional, Brandes, A., additional, Eusebi, V., additional, Ceruti, S., additional, Fainardi, E., additional, Tamarozzi, R., additional, Emiliani, E., additional, Cavallo, M., additional, Franceschi, E., additional, Tosoni, A., additional, Fiorica, F., additional, Valentini, A., additional, Depenni, R., additional, Mucciarini, C., additional, Crisi, G., additional, Sasso, E., additional, Biasini, C., additional, Cavanna, L., additional, Guidetti, D., additional, Marcello, N., additional, Pisanello, A., additional, Cremonini, A.M., additional, Guiducci, G., additional, de Pasqua, S., additional, Testoni, S., additional, Agati, R., additional, Ambrosetto, G., additional, Bacci, A., additional, Baldin, E., additional, Baldrati, A., additional, Barbieri, E., additional, Bartolini, S., additional, Bellavista, E., additional, Bisulli, F., additional, Bonora, E., additional, Bunkheila, F., additional, Carelli, V., additional, Crisci, M., additional, Dall'Occa, P., additional, de Biase, D., additional, Ferro, S., additional, Franceschi, C., additional, Frezza, G., additional, Grasso, V., additional, Leonardi, M., additional, Marucci, G., additional, Mazzocchi, V., additional, Morandi, L., additional, Mostacci, B., additional, Palandri, G., additional, Pasini, E., additional, Pastore Trossello, M., additional, Pession, A., additional, Ragazzi, M., additional, Riguzzi, P., additional, Rinaldi, R., additional, Rizzi, S., additional, Romeo, G., additional, Spagnolli, F., additional, Tinuper, P., additional, Trocino, C., additional, Cerasoli, S., additional, Dall'Agata, M., additional, Faedi, M., additional, Frattarelli, M., additional, Gentili, G., additional, Giovannini, A., additional, Iorio, P., additional, Pasquini, U., additional, Galletti, G., additional, Guidi, C., additional, Neri, W., additional, Patuelli, A., additional, Strumia, S., additional, Casmiro, M., additional, Gamboni, A., additional, Rasi, F., additional, Cruciani, G., additional, Cenni, P., additional, Dazzi, C., additional, Guidi, AR., additional, Zumaglini, F., additional, Amadori, A., additional, Pasini, G., additional, Pasquinelli, M., additional, Pasquini, E., additional, Polselli, A., additional, Ravasio, A., additional, Viti, B., additional, Sintini, M., additional, Ariatti, A., additional, Bertolini, F., additional, Bigliardi, G., additional, Carpeggiani, P., additional, Cavalleri, F., additional, Meletti, S., additional, Nichelli, P., additional, Pettorelli, E., additional, Pinna, G., additional, Zunarelli, E., additional, Artioli, F., additional, Bernardini, I., additional, Costa, M., additional, Greco, G., additional, Guerzoni, R., additional, Stucchi, C., additional, Iaccarino, C., additional, Rizzi, R., additional, Zuccoli, G., additional, Api, P., additional, Cartei, F., additional, Fallica, E., additional, Granieri, E., additional, Latini, F., additional, Lelli, G., additional, Monetti, C., additional, Ramponi, V., additional, Saletti, A., additional, Schivalocchi, R., additional, Seraceni, S., additional, Tola, M.R., additional, Urbini, B., additional, Giorgi, C., additional, Montanari, E., additional, Cerasti, D., additional, Crafa, P., additional, Dascola, I., additional, Florindo, I., additional, Mazza, S., additional, Servadei, F., additional, Silini, EM., additional, Torelli, P., additional, Immovilli, P., additional, Morelli, N., additional, and Vanzo, C., additional

Published
2014
Full Text
View/download PDF

87. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study.

Author

Ponzano, Marta, Schiavetti, Irene, Bergamaschi, Roberto, Pisoni, Enrico, Bellavia, Andrea, Mallucci, Giulia, Carmisciano, Luca, Inglese, Matilde, Cordioli, Cinzia, Marfia, Girolama Alessandra, Cocco, Eleonora, Immovilli, Paolo, Pesci, Ilaria, Scandellari, Cinzia, Cavalla, Paola, Radaelli, Marta, Vianello, Marika, Vitetta, Francesca, Montepietra, Sara, and Amato, Maria Pia

Abstract

• PM2.5, PM10 and NO2 are risk factors for Covid-19 pneumonia among MS patients. • We studied the joint exposure to the three pollutants as an environmental mixture. • The most dangerous pollutants within the mixture were NO2 and PM2.5. Many studies investigated the association between air pollution and Covid-19 severity but the only study focusing on patients with Multiple Sclerosis (MS) exclusively evaluated exposure to PM2.5. We aim to study, in a sample of MS patients, the impact of long-term exposure to PM2.5, PM10 and NO2 on Covid-19 severity, described as occurrence of pneumonia. A 1:2 ratio case-control study was designed, differentiating cases and controls based on Covid-19 pneumonia. Associations between pollutants and outcome were studied using logistic regression. Weighted quantile sum (WQS) logistic regression was used to identify the individual contribution of each pollutant within the mixture; Least Absolute Shrinkage and Selection Operator (LASSO) penalized regression was performed to confirm the variable selection from WQS. All the analyses were adjusted for confounders selected a priori. Of the 615 eligible patients, 491 patients provided detailed place of exposure and were included in the principal analysis. Higher concentrations of air pollutants were associated with increased odds of developing Covid-19 pneumonia (PM2.5: 3rd vs 1st tercile OR(95% CI)=2.26(1.29;3.96); PM10: 3rd vs 1st tercile OR(95% CI)=2.12(1.22;3.68); NO2: 3rd vs 1st tercile OR(95% CI)=2.12(1.21;3.69)). Pollutants were highly correlated with each other; WQS index was associated to an increased risk of pneumonia (β=0.44; p-value=0.004) and the main contributors to this association were NO2 (41%) and PM2.5 (34%). Consistently, Lasso method selected PM2.5 and NO2. Higher long-term exposure to PM2.5, PM10 and NO2 increased the odds of Covid-19 pneumonia among MS patients and the most dangerous pollutants were NO2 and PM2.5. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

88. A "Post-mortem" of COVID-19-associated stroke: a case-control study.

Author

Immovilli, Paolo, Marchesi, Elena, Terracciano, Chiara, Morelli, Nicola, Bazzurri, Veronica, Magnifico, Fabiola, Zaino, Domenica, Terlizzi, Emilio, De Mitri, Paola, Vollaro, Stefano, Mometto, Nicola, and Guidetti, Donata

Abstract

Objectives: To assess whether COVID-19 could be a concurrent factor in the genesis and/or worsening of stroke and to provide data on COVID-19 -associated stroke patients during the first pandemic wave and comparative data on COVID-19 negative stroke patients in the same period.Materials and Methods: This is a retrospective, observational, case-control, single centre study, carried out in a General Hospital in northern Italy. Sixty-three consecutive stroke patients were included, COVID-19-associated stroke was classified as cases and non COVID-19-associated stroke as controls.Results: A total of 19/63 (28.8%) had a COVID-19-associated stroke, 11 /63 (17.5%) were haemorrhagic and 52/63 (82.5%) ischaemic. COVID-19-associated strokes were more severe (p-value 0.019) and had a higher risk of severe disability and/or death (OR 3.79, CI 95%: 1.21-11.93, p-value 0.19). The COVID-19-associated stroke patients with onset during hospitalization for COVID-19 had a more severe stroke than patients with COVID-19 onset during hospitalization for stroke (p-value 0.019).Conclusion: Although no relationship was observed between the stroke aetiology and COVID-19, intriguingly, COVID-associated stroke turned out to be more severe and disabling. Hopefully, further studies will provide more data and help in the management of this emerging population. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

91. A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis.

Author

Ponzano, Marta, Schiavetti, Irene, Bovis, Francesca, Landi, Doriana, Carmisciano, Luca, De Rossi, Nicola, Cordioli, Cinzia, Moiola, Lucia, Radaelli, Marta, Immovilli, Paolo, Capobianco, Marco, Bragadin, Margherita Monti, Cocco, Eleonora, Scandellari, Cinzia, Cavalla, Paola, Pesci, Ilaria, Confalonieri, Paolo, Perini, Paola, Bergamaschi, Roberto, and Inglese, Matilde

Abstract

• The aim of this study was to construct such score and to evaluate its performance. • 3852 patients were included in the study and 17% of the patients required hospitalization. • This score can be used as an additional instrument to identify high-risk patients and persuade them to take important measures to prevent Covid-19 infection. Many risk factors for the development of severe forms of Covid-19 have been identified, some applying to the general population and others specific to Multiple Sclerosis (MS) patients. However, a score for quantifying the individual risk of severe Covid-19 in patients with MS is not available. The aim of this study was to construct such score and to evaluate its performance. Data on patients with MS infected with Covid-19 in Italy, Turkey and South America were extracted from the Musc-19 platform. After imputation of missing values, data were separated into training data set (70%) and validation data set (30%). Univariable logistic regression models were performed in the training dataset to identify the main risk factors to be included in the multivariable logistic regression analyses. To select the most relevant variables we applied three different approaches: (1) multivariable stepwise, (2) Lasso regression, (3) Bayesian model averaging. Three scores were defined as the linear combination of the coefficients estimated in the models multiplied by the corresponding value of the variables and higher scores were associated to higher risk of severe Covid-19 course. The performances of the three scores were compared in the validation dataset based on the area under the ROC curve (AUC) and an optimal cut-off was calculated in the training dataset for the score with the best performance. The probability of showing a severe Covid-19 course was calculated based on the score with the best performance. 3852 patients were included in the study (2696 in the training dataset and 1156 in the validation data set). 17% of the patients required hospitalization and risk factors for severe Covid-19 course were older age, male sex, living in Turkey or South America instead of living in Italy, presence of comorbidities, progressive MS, longer disease duration, higher Expanded Disability Status Scale, Methylprednisolone use and anti-CD20 treatment. The score with the best performance was the one derived using the Lasso selection approach (AUC= 0.72) and it was built with the following variables: age, sex, country, BMI, presence of comorbidities, EDSS, methylprednisolone use, treatment. An excel spreadsheet to calculate the score and the probability of severe Covid-19 is available at the following link: https://osf.io/ac47u/?view%5fonly=691814d57b564a34b3596e4fcdcf8580. The originality of this study consists in building a useful tool to quantify the individual risk for Covid-19 severity based on patient's characteristics. Due to the modest predictive ability and to the need of external validation, this tool is not ready for being fully used in clinical practice to make important decisions or interventions. However, it can be used as an additional instrument to identify high-risk patients and persuade them to take important measures to prevent Covid-19 infection (i.e. getting vaccinated against Covid-19, adhering to social distancing, and using of personal protection equipment). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

92. Intravenous Thrombolysis for Acute Ischemic Stroke in the Elderly: An Italian Cohort Study in a “Real World” Setting.

Author

Immovilli, Paolo, Rota, Eugenia, Morelli, Nicola, De Mitri, Paola, Magnifico, Fabiola, Mascolo, Andrea, Terlizzi, Emilio, Iafelice, Ilaria, Magnacavallo, Andrea, Michieletti, Emanuele, and Guidetti, Donata

Abstract

Summary Background Thrombolysis in the elderly is still a matter of debate. Recently, the Third International Stroke Trial (IST-3) suggested that recombinant tissue plasminogen activator (rt-PA) improves functional outcome, without a substantial absolute increase in symptomatic intracranial hemorrhage, even in older patients. The aim of the current prospective study is to describe safety and functional outcome in a cohort of patients treated by intravenous rt-PA in an Italian stroke unit “real world setting”. Methods All the consecutive patients treated with rt-PA between 2006 and 2010 in an Italian province with 290,000 inhabitants were enrolled. Total and symptomatic (associated with a 4-point worsening on the National Institutes of Health Stroke Scale [NIHSS] score) hemorrhages were evaluated, as safety measures, along with disability (at 3-month modified Rankin scale) as effectiveness measure. Results One hundred and eighty-seven patients were treated with rt-PA; 90 males (48.1%); average age 75.1 (±11.9) years; 79 (42.2%) patients aged ≥80 years. Patients aged ≥80 years had a higher NIHSS score at stroke onset (13.5 vs. 10.9). No significant difference was found between patients aged <80 years and ≥80 years in mortality rate ( p = 0.1), total or symptomatic intracranial hemorrhage ( p = 0.52 and p = 0.085, respectively), whereas the 3-month disability was higher in octogenarians ( p = 0.004). Conclusion Thrombolysis in patients aged ≥80 years was not associated with significantly increased intracranial hemorrhage. The higher 3-month disability rate observed in octogenarians may be explained by the more severe stroke and higher poststroke disability. Based on the current, “real world setting” study, we advocate the need for a randomized clinical trial to better clarify the efficacy and safety of intravenous thrombolysis for acute ischemic stroke in the elderly. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

96. Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH study

Author

Patti, Francesco, Chisari, Clara Grazia, Toscano, Simona, Annovazzi, Pietro, Banfi, Paola, Bergamaschi, Roberto, Clerici, Raffaella, Conti, Marta Zaffira, Cortese, Antonio, Fantozzi, Roberta, Ferraro, Diana, Fischetti, Mariano, Frigo, Maura, Gatto, Maurizia, Immovilli, Paolo, Leoni, Stefania, Malucchi, Simona, Maniscalco, Giorgia, Marfia, Girolama Alessandra, Paolicelli, Damiano, Perini, Paola, Serrati, Carlo, Totaro, Rocco, Turano, Gabriella, Valentino, Paola, Zaffaroni, Mauro, Zuliani, Cristina, and Centonze, Diego

Abstract

•Cognitive profile and physician-based and patients-reported outcomes could have a considerable impact on the disease management and on treatment decision making•According to the Control Preference Scale, more than 50% of patients who needed to change therapy chose a “collaborative” role in making treatment decision.•Cognitive profile with SDMT seems to influence patients’ preference on treatment decision.

Published
2022
Full Text
View/download PDF

98. Diagnostic Accuracy of a Bedside Screening Tool for Dysphagia (BSTD) in Acute Stroke Patients.

Author

Immovilli, Paolo, Rota, Eugenia, Morelli, Nicola, Marchesi, Elena, Terracciano, Chiara, Zaino, Domenica, Ferrari, Giampiero, Antenucci, Roberto, and Guidetti, Donata

Abstract

Background and Purpose: an estimated 40-80% of acute ischemic stroke patients have dysphagia and about 14% develop stroke-associated pneumonia. However, it may be difficult to detect swallowing problems at admission. Moreover, there might not be an on-duty specialist skilled in the diagnosis of this condition. This study aimed at developing a user-friendly bedside examination to identify the risk of dysphagia in stroke patients at hospital admission.Methods: a diagnostic accuracy study was carried out to assess the concurrent validity of a simple Bedside Screening Tool for Dysphagia (BSTD) in acute stroke. All the consecutive stroke patients admitted between January and April 2018 were enrolled. Sensitivity, specificity, positive (PPV), negative predictive values (NPV) and the Cohen K concordance index scores, reported by nurses and speech-pathologists, were assessed.Results: a total of 67/120 patients (55.8%) were male; overall average age was 67.4 (range 45-91) and 80.8% of the whole population had a history of ischemic stroke. The nursing staff identified 33.3% of dysphagia cases at admission and the speech pathologists 30%. The Cohen K was 0.92 (optimal concordance when K was > 0.8), sensitivity was 100%, specificity 95.2%, PPV 90% and NPV 100%.Conclusions: our BSTD had a 100% negative predictive value, indicating that this screening test is very useful in ruling out/confirming dysphagia in acute stroke patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

99. Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study).

Author

Patti, Francesco, Chisari, Clara Grazia, D'Amico, Emanuele, Annovazzi, Pietro, Banfi, Paola, Bergamaschi, Roberto, Clerici, Raffaella, Conti, Marta Zaffira, Cortese, Antonio, Fantozzi, Roberta, Fischetti, Mariano, Frigo, Maura, Gatto, Maurizia, Immovilli, Paolo, Leoni, Stefania, Malucchi, Simona, Maniscalco, Giorgia, Marfia, Girolama Alessandra, Paolicelli, Damiano, and Perini, Paola

Abstract

• The introduction of increasingly effective treatments has changed the MS scenario. • This study investigated the reasons that brought about modification of treatment. • In our study, out of 13,657 patients, 336 (3%) modified treatment. • 90.2% switched, 8.9% temporarily discontinued, and 0.9% permanently discontinued. • Efficacy remains the main driving force behind switching in 58.4% of patients. clinical factors and frequency of disease-modifying therapy (DMT) changes/interruptions in relapsing-remitting multiple sclerosis (RRMS) patients have not been well defined. The aim of this study was to describe reasons of MS treatment modifications in a large cohort of Italian MS patients. this multicenter, cross-sectional non interventional study (SWITCH) conducted at 28 Italian MS centers, screened, by visit/telephone contact between June 2016 and June 2017, all RRMS patients receiving stable DMT treatment and enrolled patients with change in DMT treatment. out of 13,657 recorded in the log, 409 (3%) changed therapy. Of these, 336 (2.5%), met the study criteria and were considered eligible. Among 303 (90.2% of 336) patients switching, the most common reason was "lack of efficacy" (58.4% of 303). Among 30 (8.9%) patients who interrupted treatment temporarily, the most common reason was pregnancy (40.0% of 30). Out of 3 (0.9%) patients who discontinued treatment permanently, 2 (66.7%) had as first reason as "patient decision". Multivariate analysis showed that EDSS was the only variable with statistically significant effect on changing treatments (r = 8.33; p -value of Type III Sum of Squares = 0.016). in our study, 303 (90.2% of eligible patients) switched treatment, 30 (8.9%) interrupted treatment temporarily, and 3 (0.9%) discontinued treatment permanently. Efficacy remains the main driving force behind switching behavior, as the primary aim of treatment is to be disease free or reduce disease activity. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results